Skip to main content

Featured Article: Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy


New Content Item

Mortality associated with pancreatic cancer is among the highest of all malignancies, with a 5-year overall survival of 5–10%. Immunotherapy, represented by the blocking antibodies against programmed cell death protein 1 or its ligand 1 (anti-PD-(L)1), has achieved remarkable success in a number of malignancies. However, due to the immune-suppressive tumor microenvironment, the therapeutic efficacy of anti-PD-(L)1 in pancreatic cancer is far from expectation. To address such a fundamental issue, chemotherapy, radiotherapy, targeted therapy and even immunotherapy itself, have individually been attempted to combine with anti-PD-(L)1 in preclinical and clinical investigation. 

This review, with a particular focus on pancreatic cancer therapy, collects current anti-PD-(L)1-based combination strategy, highlights potential adverse effects of accumulative combination, and further points out future direction in optimization of combination, including targeting post-translational modification of PD-(L)1 and improving precision of treatment.

Aims and scope

Journal of Experimental & Clinical Cancer Research is an online peer-reviewed journal that provides a high-quality forum for all aspects of basic, clinical and translational work in oncology.

Please click here to read more.

Editor-in-Chief

Mauro Castelli, Regina Elena National Cancer Institute, Italy

If you would like to contact Journal of Experimental & Clinical Cancer Research, please send an email to: 

editorialjeccr@gmail.com

Articles

Springer Nature Oncology Portfolio

Discover the range of academic oncology titles at Springer Nature here.

Colorectal Cancer Awareness Month

In recognition of Colorectal Cancer Awareness Month this March, we have selected a collection of articles on colorectal cancer from across our open access portfolio. Together, these articles contribute to the evolving landscape of colorectal cancer research and the fight against this prevalent and impactful disease.
© Mopic / stock.adobe.com

Call for papers: Charting the Tumor Immune Microenvironment: Advances in Spatial Profiling and Novel Therapeutic Avenues

New Content Item

Journal of Experimental & Clinical Cancer Research is delighted to announce a new thematic series focused on: 

Charting the Tumor Immune Microenvironment: Advances in Spatial Profiling and Novel Therapeutic Avenues 

The Special Issue will accept Research Articles and Reviews in this topic. Submit here

  • Submission opens: 1st July 2024 
  • Submission deadline: 30th June 2025 

Click here to view this collection. Click here to access all thematic series published to date in Journal of Experimental & Clinical Cancer Research. 

Call for papers: Liquid Biopsy in Precision Oncology

New Content Item

Journal of Experimental & Clinical Cancer Research is delighted to announce a new thematic series focused on:

Liquid Biopsy in Precision Oncology

The Special Issue will accept Research Articles and Reviews in this topic. Submit here.

  • Submission opens: 1st February 2024
  • Submission deadline: 31st January 2025

Click here to view this collection. Click here to access all thematic series published to date in Journal of Experimental & Clinical Cancer Research.

Follow JECCR on Social Media

Social Media IconsTwitter

Facebook

LinkedIn

Follow JECCR's social media accounts to be kept up-to-date with the latest articles, collections and journal news!

Recognising Editorial Excellence

SN Editorial Excellence badgeJournal of Experimental & Clinical Cancer Research is a top rated Springer Nature journal. Prof. Mauro Castelli and the editorial team performed in the top percentile of journals based on data collected from the Journal Author Satisfaction Survey. We are recognising extraordinary editors for their commitment and passion to their journals. Read more about editorial excellence here.

Reviewer Acknowledgement and New Recruitment

The Editor-in-Chief of Journal of Experimental & Clinical Cancer Research would like to thank all of our reviewers who have contributed to the journal and is looking for new reviewers to assess manuscripts. For consideration, please send your CV with keywords and expertise to editorialjeccr@gmail.com

Archival content

Journal of Experimental & Clinical Cancer Research has been publishing since 1982.  Prior to publishing with BioMed Central from 2008, Journal of Experimental & Clinical Cancer Research was published in print.  For enquiries about previous content, please contact us on: 

editorialjeccr@gmail.com


Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 11.4
    5-year Journal Impact Factor: 11.4
    Source Normalized Impact per Paper (SNIP): 1.770
    SCImago Journal Rank (SJR): 2.806

    Speed 2023
    Submission to first editorial decision (median days): 5
    Submission to acceptance (median days): 100

    Usage 2023
    Downloads: 3,003,080
    Altmetric mentions: 3,022